These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 21879841)
1. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro- 8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids. Senthilkumar P; Dinakaran M; Chandraseakaran Y; Yogeeswari P; Sriram D Arch Pharm (Weinheim); 2009 Feb; 342(2):100-12. PubMed ID: 19137533 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis. Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749 [TBL] [Abstract][Full Text] [Related]
4. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro antitubercular activity of a series of quinoline derivatives. de Souza MV; Pais KC; Kaiser CR; Peralta MA; de L Ferreira M; Lourenço MC Bioorg Med Chem; 2009 Feb; 17(4):1474-80. PubMed ID: 19188070 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Upadhayaya RS; Kulkarni GM; Vasireddy NR; Vandavasi JK; Dixit SS; Sharma V; Chattopadhyaya J Bioorg Med Chem; 2009 Jul; 17(13):4681-92. PubMed ID: 19457676 [TBL] [Abstract][Full Text] [Related]
7. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D Bioorg Med Chem; 2008 Mar; 16(6):3408-18. PubMed ID: 18304818 [TBL] [Abstract][Full Text] [Related]
8. Shortening the treatment of tuberculosis. Mitchison DA Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148 [No Abstract] [Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
10. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Ganihigama DU; Sureram S; Sangher S; Hongmanee P; Aree T; Mahidol C; Ruchirawat S; Kittakoop P Eur J Med Chem; 2015 Jan; 89():1-12. PubMed ID: 25462220 [TBL] [Abstract][Full Text] [Related]
11. L-proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines. Indumathi S; Perumal S; Banerjee D; Yogeeswari P; Sriram D Eur J Med Chem; 2009 Dec; 44(12):4978-84. PubMed ID: 19781824 [TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
13. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies. Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083 [TBL] [Abstract][Full Text] [Related]
14. Conformationally-constrained indeno[2,1-c]quinolines--a new class of anti-mycobacterial agents. Upadhayaya RS; Lahore SV; Sayyed AY; Dixit SS; Shinde PD; Chattopadhyaya J Org Biomol Chem; 2010 May; 8(9):2180-97. PubMed ID: 20401395 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Upadhayaya RS; Vandavasi JK; Vasireddy NR; Sharma V; Dixit SS; Chattopadhyaya J Bioorg Med Chem; 2009 Apr; 17(7):2830-41. PubMed ID: 19285414 [TBL] [Abstract][Full Text] [Related]
16. Ring-substituted quinolines as potential anti-tuberculosis agents. Vangapandu S; Jain M; Jain R; Kaur S; Singh PP Bioorg Med Chem; 2004 May; 12(10):2501-8. PubMed ID: 15110831 [TBL] [Abstract][Full Text] [Related]
17. Microbiology. TB--a new target, a new drug. Cole ST; Alzari PM Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490 [No Abstract] [Full Text] [Related]
18. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines. Nayyar A; Monga V; Malde A; Coutinho E; Jain R Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805 [TBL] [Abstract][Full Text] [Related]
19. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and 3D-QSAR analysis of 2-chloroquinoline derivatives as H37 RV MTB inhibitors. Khunt RC; Khedkar VM; Coutinho EC Chem Biol Drug Des; 2013 Dec; 82(6):669-84. PubMed ID: 23790070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]